ReviewCancers2021
A Review on the Current Treatment Paradigm in High-Risk Prostate Cancer.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Curcumin-releasing oxidized konjac/GelMA hydrogel for ROS-mediated suppression of postoperative prostate cancer recurrence and metastasis.International journal of pharmaceutics: X · 2026Article
- Early Identification and Management of Biochemical Recurrence Following Radical Prostatectomy.Annals of surgical oncology · 2026Review
- Reprogramming the Evolution of High-Risk Prostate Cancer: Multidisciplinary Strategies to Delay Castration Resistance.Journal of clinical medicine · 2026Review
- An efficient automated approach for accumulated dose estimation in prostate cancer radiotherapy.Physics and imaging in radiation oncology · 2026Article
- PD-L1 Expression in Prostate Cancer: Anatomopathological Features, Methodological Pitfalls, and Therapeutic Potential.International journal of molecular sciences · 2026Review
- Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next.NPJ vaccines · 2026Review
- Impact of Testosterone Recovery on Oncologic Outcomes in High-Risk, Localized Prostate Cancer.The Prostate · 2025Article
- A Synergistic Strategy Combining Chemotherapy and Photodynamic Therapy to Eradicate Prostate Cancer.International journal of molecular sciences · 2024Article
- Computed Tomography-Based Radiomics for Long-Term Prognostication of High-Risk Localized Prostate Cancer Patients Received Whole Pelvic Radiotherapy.Journal of personalized medicine · 2023Article
- The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer.Current oncology (Toronto, Ont.) · 2023Review
- Article
- Inhibition of CXCR4 Enhances the Efficacy of Radiotherapy in Metastatic Prostate Cancer Models.Cancers · 2023Article
- Article
- Personalized 3-Gene Panel for Prostate Cancer Target Therapy.Current issues in molecular biology · 2022Article
- The Impact of Metabolic Syndrome and Type 2 DiabetesFrontiers in cell and developmental biology · 2022Review
- Neoadjuvant Chemohormonal Therapy for Patients With Very-high Risk Localized Prostate Cancer in Clinical Stages T2 and T3a.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-risk prostate cancer is traditionally treated with a combination of radiotherapy (RT) and androgen deprivation therapy (ADT). However, recent advancements in systemic treatment and radiotherapy have widened the spectrum of treatment for this patient population. Use of image guidance and intensity modulation, as well as the incorporation of brachytherapy, has led to safe radiotherapy dose escalation with reduced risk of recurrence. Clinical trials have helped define the role of pelvic nodal radiotherapy, the role of stereotactic ablative radiotherapy, and the optimal duration and sequencing of ADT in combination with radiotherapy. Emerging evidence has redefined the role of surgery in this cohort. Contemporary clinical trials have identified new systemic therapy options in high-risk prostate cancer. Finally, new imaging modalities including multi-parametric MRI and molecular imaging and genomic classifiers have ushered a new era in patient selection, risk stratification, and treatment tailoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.